Clinical Context
A 48-year-old patient with progressive asymmetric limb weakness, fasciculations, and dysarthria is referred to a neuromuscular clinic for evaluation of suspected amyotrophic lateral sclerosis (ALS). The neurologist documents a detailed history, neurologic exam, and electromyography that support a motor neuron disease process. Genetic counseling is provided and written informed consent is obtained for targeted and panel genetic testing to assess for pathogenic variants associated with familial and sporadic ALS. A peripheral blood sample is collected in the clinic or an outpatient laboratory and sent to a certified molecular diagnostic laboratory for analysis under billing code S3800 (Genetic testing for amyotrophic lateral sclerosis).
The typical workflow includes: pre-test genetic counseling, specimen collection and labeling, shipping to the reference laboratory, laboratory testing (single-gene sequencing and/or multigene panel including common ALS genes such as C9orf72, SOD1, TARDBP, FUS), reporting of results with interpretation, and post-test counseling to discuss pathogenic, likely pathogenic, variant of uncertain significance, or negative results. Results may impact family counseling, cascade testing of relatives, clinical prognosis, and eligibility for gene-targeted clinical trials. The typical site of service is an outpatient neurology clinic or an ambulatory phlebotomy/laboratory collection center. Frequently involved providers include neurologists, genetic counselors, and clinical laboratory specialists.